Team:UC Davis

From 2009.igem.org

(Difference between revisions)

Latest revision as of 18:07, 21 October 2009

Homepage_UCdavis

            It is estimated that about one in every 133 Americans suffer from an autoimmune disorder called Celiac Disease (14, 11). Celiac Disease is a condition in which the small intestines of an affected individual cannot properly digest gliadin, a protein present in gluten. When consumed, gliadin induces immune system responses, the side-effects of which are, but not limited to: abdominal pain, chronic diarrhea, and vomiting (14). Currently, the only accepted treatment for this disorder is adhering to a gluten-free diet (14, 12). This can be very difficult as great varieties of food contain gluten. This inspired us to imagine an alternative treatment based on a probiotic organism that can survive and take residence in the stomach, where it would secrete an enzyme that degrades gliadin.
           Then the design elements of this organism should satisfy at least two main criteria. First, it should be able to survive only in the stomach; second, it should secrete an enzyme that degrades gliadin. We envision that these parts would not only be useful for our project, but also to other future projects.
       We decided to focus our summer project on building the first of the two key elements required for our system:
                1. Produce an inducible secretion system
                2. Construct a biological pH sensor limiting this secretion system to the stomach

UC Davis iGEM team is sponsored by:

We want to thank Marc Facciotti for his helpful advice.
Special thanks to Suzy Fenton,Wayne Fenton, Jeanne Joe-Fenton and Wayne Fenton Jr.
Also we thank Charles H. Halsted for reviewing our material regarding celiac disease.

@@ Line 10: / Line 10: @@
 </span><b style="color: rgb(255, 255, 153);"><span
 style="font-size: 13.5pt; font-family: &quot;Times New Roman&quot;,&quot;serif&quot;;"></span></b><span
-style="color: rgb(255, 255, 153);"><img
+style="color: rgb(255, 255, 153);"><img src="" alt=""
-src="" alt=""
 style="width: 151px; height: 161px;"></span><b
 style="color: rgb(255, 255, 153);"><span
@@ Line 56: / Line 55: @@
 style="color: rgb(0, 0, 0);"><span
 style="font-size: 13.5pt; font-family: &quot;Times New Roman&quot;,&quot;serif&quot;;"><big><big><big><big><small>
-<img style="width: 191px; height: 147px;" alt=""
+<img style="width: 191px; height: 147px;" alt="" src=""><br>
-src=""><br>
 </small></big></big></big></big></span></b></div>
 <hr style="width: 100%; height: 2px;"><b style="color: rgb(0, 0, 0);"><span
@@ Line 77: / Line 75: @@
 every 133 Americans suffer from an autoimmune disorder called Celiac
 Disease
-(14, 11). Celiac Disease is a condition where the small intestines of
+(14, 11). Celiac Disease is a condition in which the small intestines of
 an
-affected individual cannot properly digest gliadin, a protein present in gluten.
+affected individual cannot properly digest gliadin, a protein present
+in gluten.
 When
-consumed, gliadin induces immune system responses, whose
+consumed, gliadin induces immune system responses, the
-side-effects are,
+side-effects of which are,
-but not limited to abdominal pain, chronic diarrhea and vomiting (14).
+but not limited to: abdominal pain, chronic diarrhea, and vomiting (14).
 Currently, the only accepted treatment for this disorder is adhering to
 a
@@ Line 94: / Line 92: @@
 survive and take residence in the stomach, where it would secrete an
 enzyme that
-will degrade gliadin.</big></span><big style="font-weight: bold;"><span
+degrades gliadin.</big></span><big style="font-weight: bold;"><span
 style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;;"><br>
 &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp; Then the design
-elements of this organism should be able to satisfy at least two main
+elements of this organism should satisfy at least two main
 criteria.
 First, it
-should be able to survive ONLY in the stomach and, secondly, secrete an
+should be able to survive only in the stomach; second, it should secrete an
 enzyme
-that can degrade gliadin<i>.</i> We envision that these parts would not
+that degrades gliadin<i>.</i> We envision that these parts would
-only be useful for our purpose probiotic, but could be useful to number
+not
-of other projects.</span><span
+only be useful for our project, but also to other future projects.</span><span
 style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;;"><o:p></o:p></span><br>
 </big><span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;;"><big
 style="font-weight: bold;">&nbsp;&nbsp;&nbsp;
 &nbsp; &nbsp;
-&nbsp;&nbsp; We have
+&nbsp;&nbsp; We decided to focus our summer project on building the
-decided to focus our summer project on building two key elements
+first of the two key elements
 required for
-our “dream bug”. Therefore, our project has been split into two tasks:<o:p></o:p><br>
+our system:<o:p></o:p><br>
 &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;
 &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; 1. <a
@@ Line 123: / Line 121: @@
 biological pH sensor limiting this secretion system to
 the
-stomach</a><br>
+stomach</a></big></span><a
+href="https://2009.igem.org/Team:UC_Davis/ph_sensor1"><span
+style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;;"><span
+style="text-decoration: underline;"></span></span></a><span
+style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;;"><big
+style="font-weight: bold;"><br>
 </big></span></p>
 <p class="MsoNormal"
@@ Line 131: / Line 134: @@
 style="color: rgb(0, 0, 0);"><span
 style="font-size: 13.5pt; font-family: &quot;Times New Roman&quot;,&quot;serif&quot;;"></span></b></a><span
-style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
-<span style="text-decoration: underline;"><a
+&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
+&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
+&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
+&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
+&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
+&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+&nbsp;</span><a href="https://2009.igem.org/Team:UC_Davis/ph_sensor1"><span
+style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;;"><span
+style="text-decoration: underline;"></span></span></a><a
 href="https://2009.igem.org/Team:UC_Davis/Project_Summary"><img alt=""
 src="https://static.igem.org/mediawiki/2009/a/ac/UCDAVIS_summary.png"
-style="border: 0px solid ; width: 132px; height: 101px;"></a><br>
+style="border: 0px solid ; width: 63px; height: 50px;"></a><span
+style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+<span style="text-decoration: underline;"><br>
 </span> </span><a href="https://2009.igem.org/Team:UC_Davis/ph_sensor1"><b
 style="color: rgb(0, 0, 0);"><span
@@ Line 170: / Line 183: @@
 style="width: 182px; height: 108px;" alt=""
 src="https://static.igem.org/mediawiki/2009/c/c6/UCDAVIS_genome_center.jpg"><br>
-<font size="-1">Special thanks to <span style="font-weight: bold;">Suzy
+<font size="-1">We want to thank <span style="font-weight: bold;">Marc</span>
+<span style="font-weight: bold;">Facciotti</span> for his helpful
+advice.<br>
+Special thanks to <span style="font-weight: bold;">Suzy
 Fenton</span>,<span style="font-weight: bold;">Wayne Fenton, Jeanne
 Joe-Fenton </span>and<span style="font-weight: bold;"> Wayne Fenton Jr.</span>